Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 189

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 2
Chunk 189
---
 arrangements. The following table provides information regarding our revenues during the three and six months ended months ended June 30, 2025 (dollars in thousands):Three Months Ended June 30,ChangeSix Months EndedJune 30,Change20252024AmountPercent20252024AmountPercentNet product salesQelbree$77,547 $59,395 $18,152 31%$142,292 $104,499 $37,793 36%GOCOVRI36,660 31,703 4,957 16%67,349 58,265 9,084 16%APOKYN12,820 17,295 (4,475)(26)%27,796 33,944 (6,148)(18)%Trokendi XR11,193 17,086 (5,893)(34)%23,994 33,075 (9,081)(27)%Oxtellar XR11,637 29,516 (17,879)(61)%21,835 56,459 (34,624)(61)%ONAPGO1,604 — 1,604 100 %1,604 — 1,604 100 %Other(1)6,534 7,543 (1,009)(13)%15,113 14,757 356 2%Total net product sales157,995 162,538 (4,543)(3)%299,983 300,999 (1,016)—%Royalty, licensing and other revenues7,458 5,787 1,671 29%15,294 10,970 4,324 39%Total revenues$165,453 $168,325 $(2,872)(2)%$315,277 $311,969 $3,308 1%___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Net Product Sales

Net product sales were $158.0 million and $162.5 million for the three months ended June 30, 2025 and 2024, respectively. Net product sales were $300.0 million and $301.0 million for the six months ended June 30, 2025 and 2024, respectively. The decrease in both periods was primarily due to the decline in net product sales of APOK